Onkologie. 2022:16(4):195-199 | DOI: 10.36290/xon.2022.037

Genetic testing in ovarian cancer

Jana Soukupová
Laboratoř onkogenetiky, Ústav lékařské biochemie a laboratorní diagnostiky, 1. LF UK a VFN v Praze

Ovarian cancer is a disease with a significant hereditary component. Hereditary mutations in clinically relevant genes (including BRCA1 and BRCA2) are found in one in four patients in our population. Therefore, genetic testing for germline mutations is indicated for every patient with this disease (epithelial ovarian, fallopian tube or peritoneal cancer), regardless of the histopathological type of ovarian tumour or age at diagnosis. Nearly one in five patients (up to 20% of all patients with ovarian cancer) carries a pathogenic germline mutation in the BRCA1 and BRCA2 genes. Genetic testing has prognostic and predictive value for the patient herself. Carriers of mutations in the BRCA1 and BRCA2 genes generally respond better to treatment with platinum derivatives, and this treatment can be applied in higher lineages. In addition, genetic testing of germline mutations allows targeted genetic counselling in the patient`s family, identification of individuals at risk and appropriate surveillance management of the patient and her positively tested healthy relatives. Germline as well as somatic mutations in BRCA1 and BRCA2 genes may also play a role in the consideration of the indication of a specific poly-ADP-ribose polymerase inhibitor (PARPi). Somatic mutations in BRCA1 and BRCA2 are found in an additional 5-9% of women with ovarian cancer. Simultaneous testing for germline and somatic mutations will allow for more efficient identification of patients who are potential candidates for one type of PARPi maintenance therapy, while also detecting healthy relatives at high risk of developing breast and ovarian cancer in particular.

Keywords: ovarian cancer, germline mutation, somatic mutation, predisposition genes, genetic testing, indication.

Accepted: August 22, 2022; Published: August 24, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Soukupová J. Genetic testing in ovarian cancer. Onkologie. 2022;16(4):195-199. doi: 10.36290/xon.2022.037.
Download citation

References

  1. Ramus SJ, Harrington PA, Pye C, et al. Contribution of BRCA1 and BRCA2 mutations to inherited ovarian cancer. Hum Mutat. 2007;28(12):1207-1215. Go to original source... Go to PubMed...
  2. Lhotova K, Stolarova L, Zemankova P, et al. Multigene Panel Germline Testing of 1333 Czech Patients with Ovarian Cancer. Cancers (Basel). 2020;12(4). doi: 10.3390/cancers12040956. PubMed PMID: 32295079; PubMed Central PMCID: PMCPMC7226062. Go to original source... Go to PubMed...
  3. Kurman RJ, Shih Ie M. The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded. The American journal of pathology. 2016;186(4):733-747. Go to original source... Go to PubMed...
  4. Foretova L, Machackova E, Palacova M, et al. Recommended Extension of Indication Criteria for Genetic Testing of BRCA1 and BRCA2 Mutations in Hereditary Breast and Ovarian Cancer Syndrome. Klin Onkol. 2016;29 Suppl 1:S9-13. Go to original source... Go to PubMed...
  5. Eccleston A, Bentley A, Dyer M, et al. A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer. Value Health. 2017;20(4):567-576. Go to original source... Go to PubMed...
  6. Frey MK, Finch A, Kulkarni A, et al. Genetic Testing for All: Overcoming Disparities in Ovarian Cancer Genetic Testing. American Society of Clinical Oncology Educational Book. 2022;(42):1-12. Go to original source... Go to PubMed...
  7. Kurian AW, Ward KC, Howlader N, et al. Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2019;37(15):1305-1315. Go to original source... Go to PubMed...
  8. Manchanda R, Menon U. Setting the Threshold for Surgical Prevention in Women at Increased Risk of Ovarian Cancer. Int J Gynecol Cancer. 2018;28(1):34-42. Go to original source... Go to PubMed...
  9. Soukupova J, Zemankova P, Lhotova K, et al. Validation of CZECANCA (CZEch CAncer paNel for Clinical Application) for targeted NGS-based analysis of hereditary cancer syndromes. PloS one. 2018;13(4):e0195761. Go to original source... Go to PubMed...
  10. Soukupova J, Zemankova P, Kleiblova P, et al. CZECANCA: CZEch CAncer paNel for Clinical Application- Design and Optimization of the Targeted Sequencing Panel for the Identification of Cancer Susceptibility in High-risk Individuals from the Czech Republic. Klin Onkol. 2016;29 Suppl 1:S46-54. Go to original source... Go to PubMed...
  11. Zikan M. Doporučení genetické testace u pacientek s gynekologickým zhoubným nádorem. Česká gynekologie. 2015;80(2):97-103. Go to PubMed...
  12. Nyberg T, Frost D, Barrowdale D, et al. Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study. Eur Urol. 2020;77(1):24-35. Go to original source... Go to PubMed...
  13. Bolton KL, Chenevix-Trench G, Goh C, et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA. 2012;307(4):382-390. Go to original source... Go to PubMed...
  14. Matulonis U, Herrstedt J, Oza A, et al. Long-term safety and secondary efficacy endpoints in the ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian cancer. Gynecologic oncology. 2021;162:S24-S5. Go to original source...
  15. Akay M, Funingana IG, Patel G, et al. An In-Depth Review of Niraparib in Ovarian Cancer: Mechanism of Action, Clinical Efficacy and Future Directions. Oncology and Therapy. 2021;9(2):347-364. Go to original source... Go to PubMed...
  16. Dundr P, Ryška A, Prausová J, et al. Možnosti molekulárního testování somatických aberací v nádorové tkáni metodou NGS v rutinní praxi - aktuální situace v České republice. Česko-slovenská patologie. 2021;57(3):147-149.
  17. Chandrasekaran D, Sobocan M, Blyuss O, et al. Implementation of Multigene Germline and Parallel Somatic Genetic Testing in Epithelial Ovarian Cancer: SIGNPOST Study. Cancers (Basel). 2021;13(17). Go to original source... Go to PubMed...
  18. Lincoln SE, Nussbaum RL, Kurian AW, et al. Yield and Utility of Germline Testing Following Tumor Sequencing in Patients With Cancer. JAMA Netw Open. 2020;3(10): e2019452. Go to original source... Go to PubMed...
  19. Kleibl Z, Kristensen VN. Women at high risk of breast cancer: Molecular characteristics, clinical presentation and management. Breast. 2016;28:136-144. Go to original source... Go to PubMed...
  20. Zikan M. Gynecological Care and Prevention of Gynecological Malignancies in BRCA1 and BRCA2 Mutation Carriers. Klin Onkol. 2016;29 Suppl 1:S22-30. Go to original source... Go to PubMed...
  21. Domchek SM, Friebel TM, Neuhausen SL, et al. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. The Lancet Oncology. 2006;7(3):223-229. Go to original source... Go to PubMed...
  22. Lincoln SE, Hambuch T, Zook JM, et al. One in seven pathogenic variants can be challenging to detect by NGS: an analysis of 450,000 patients with implications for clinical sensitivity and genetic test implementation. Genetics in medicine: official journal of the American College of Medical Genetics. 2021;23(9):1673-1680. Go to original source... Go to PubMed...
  23. Li MM, Datto M, Duncavage EJ, et al. Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2017;19(1):4-23. Go to original source... Go to PubMed...
  24. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics in medicine: official journal of the American College of Medical Genetics. 2015;17(5):405-424. Go to original source... Go to PubMed...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.